Enzymes, Signaling Proteins, Extracellular Ligands, Signaling Reagents, Antibodies

Name	Catalog Number	CAS Registration Number	Molecular Formula	Purity	Chemical Name
6BIO	G08-900	667463-62-9	C₁₆H₁₀BrN₃O₂	98% (TLC: 5% CH₃OH₃ in CH₂Cl₂, R_f=0.43); NMR (Conforms)	(2'Z,3'E)-6-Bromoindirubin-3'-oxime
7-CL-O-Nec-1	R07-901B	852391-15-2	C₁₃H₁₂ClN₃O	>98% (TLC); NMR (Conforms)	Nec-1s; 5-((7-Chloro-1H-indol-3-yl)methyl)-3-methylimidazolidine-2,4-dione
A83-01	A09-900	909910-43-6	C₂₅H₁₉N₅S	>98% (TLC); NMR (Conforms)	3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide
AAL-993	F11-900C	269390-77-4	C₂₀H₁₆F₃N₃O	>98% (TLC); NMR (Conforms)	2-((4-Pyridyl)methyl)amino-N-(3 (trifluoromethyl)phenyl)benzamide
AG-1296	P12-900	146535-11-7	C₁₆H₁₄N₂O₂	>98% (TLC); NMR (Conforms)	6,7-Dimethoxy-3-phenylquinoxaline
AG-1478	E10-900B	175178-82-2	C₁₆H₁₄ClN₃O₂	>98% (TLC); NMR (Conforms)	1. N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinanine 2. Free Base
AG-1517	K11-900B	153436-54-5	C₁₆H₁₄BrN₃O₂ ∙ HCl	>98% (TLC); NMR (Conforms)	1. 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline hydrochloride 2. PD-153,035 3. SU-5271 4. ZM-252868
AG-490	J02-901	133550-30-8	C₁₇H₁₄N₂O₃	>98% (TLC); NMR (Conforms)	(E)-2-Cyano-3-(3,4-dihydrophenyl)-N-(phenylmethyl)-2-propenamide
AG-879	N28-909B	148741-30-4	C₁₈H₂₄N₂OS	>99% (TLC); NMR (Conforms)	alpha-Cyano-(3,5-di-t-butyl-4-hydroxy)thiocinnamide
Alsterpaullone	G09-901C	237430-03-4	C₁₆H₁₁N₃O₃	>96% (TLC); NMR (Conforms)	9-Nitro-7,12-dihydroindolo-[3,2-d][1] benzazepin-6(5)-one
Amlexanox	T02-901	68302-57-8	C₁₆H₁₄N₂O₄	>98% (TLC); NMR (Conforms)	2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano[2,3-b]pyridine-3-carboxylic acid
Apigenin	K10-900C	520-36-5	C₁₅H₁₀O₅	>98% (TLC); NMR (Conforms)	4',5,7-Trihydroxyflavone
AR-A014418	G09-901	487021-52-3	C₁₂H₁₂N₄O₄S	>98% (TLC); NMR (Conforms)	N-[(4-Methoxyphenyl) methyl]-N'-(5-nitro-2-thiazolyl) urea
AS-041164	P29-901	6318-41-8	C₁₁H₇NO₄S	>98% (TLC); NMR (Conforms)	1. 5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione 2. NSC31098
AS-605240	P27-901	648450-29-7	C12H7N3O2S	>98% (TLC); NMR (conforms)	5-(6-Quinoxalinylmethylene)-2,4-thiazolidine-2,4-dione
BAY 11-7082	C51-900	19542-67-7	C₁₀H₉NO₂S	>98% (TLC); NMR (Conforms)	(E)-3-[(4-methylphenylsulfonyl]-2-propenenitrile
BML-259	C33-901	267654-00-2	C₁₄H₁₆N₂OS	>98% (TLC: 5% CH3OH/CH2Cl2; Rf=0.46); NMR (Conforms)	N-(5-Isopropylthiazol-2-yl) phenylacetamide
BML-277	C48-901	516480-79-8	C₂₀H₁₄ClN₃O₂	≥98% (TLC; 1:1 ethylacetate: hexane; Rf=0.17); NMR (Conforms)	1. 2-(4-(4-chlorophenoxy)phenyl)-1H-benzimidazole-5-carboxamide 2. Chk2 Inhibitor II
BRD-7389	R15-901	376382-11-5	C₂₄H₁₈N₂O₂	>98% (TLC); NMR (Conforms)	1-[(2-Phenylethyl)amino]-3H-naphtho[1,2,3-de]quinoline-2,7-dione
CHIR-99021	G09-901B	252917-06-9	C₂₂H₁₈Cl₂N₈	>98% (TLC); NMR (Conforms)	6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl] amino] ethyl] amino]-3-pyridinecarbonitrile
CID-2011756	P72-901	638156-11-3	C₂₂H₂₁ClN₂O₃	≥98% (TLC); NMR (Conforms)	5-(3-Chlorophenyl)-N-[4-(4-morpholinylmethyl) phenyl]-2-furancarboxamide
CZC-54252 HCl	L10-901	1199911-27-9	C₂₂H₂₅ClN₆O₄S ∙ HCl	≥98% (TLC); NMR (Conforms)	N-[-[[5-Chloro-2-[[2-methoxy-4-(4-morpholinyl) phenyl] amino]-4-pyrimidinyl] amino] phenyl] methanesulfonamide hydrochloride
Dabrafenib	B08-901	1195765-45-7	C₂₃H₂₀F₃N₅O₂S₂	>98% (TLC); NMR (conforms)	N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide; GSK2118436
Dasatinib	S19-901B	302962-49-8	C₂₂H₂₆ClN₇O₂S	>98% (TLC); NMR (Conforms)	1. N-(2-chloro-6-methylphneyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide; 2. BMS-354825
Deguelin	A16-900B	522-17-8	C₂₃H₂₂O₆	>98% (TLC); NMR (Conforms)	None
Dibutyryl cAMP	P51-901	16980-89-5	C18H23N5O8P · Na	>98% (HPLC); NMR (conforms)	N6, O2’-Dibutyryl adenosine 3’, 5’-cyclic monophosphate sodium salt; Bucladesine Na
Dimethylsphingosine	S17-900	119567-63-4	C₂₀H₄₁NO₂	>98% (TLC); NMR (Conforms)	(2S,3R,E)-2-(dimethylamino)octadeca-4-ene-1,3,diol
DMPQ 2 HCl	P13-901	137206-97-4	C₁₆H₁₄N₂O₂ ∙2HCl	>98% (TLC); NMR (Conforms)	5,7-Dimethoxy-3-(4-pyridinyl) quinoline dihydrochloride
Doramapimod	M39-900	285983-48-4	C₃₁H₃₇N₅O₃	>98% (TLC); NMR (Conforms)	1. 1-[5-tert-butyl-2-(4-methylphenyl) pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy) naphthalen-1-yl] urea 2. BIRB-796
Dorsomorphin	P47-900	866405-64-3	C₂₄H₂₅N₅O	>98% (TLC); NMR (Conforms)	1. 6-[4-[2-(1-Piperidinyl) ethoxy] phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a] pyrimidine 2. BML-275
Erlotinib HCl	E10-900C	183319-69-9	C₂₂H₂₃N₃O₄ ∙ HCl	>98% (TLC); NMR (Conforms)	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine, hydrochloride
Everolimus	F17-901D	159351-69-6	C53H83NO14	≥98% (HPLC); NMR (Conforms)	40-O-(2-hydroxyethyl)rapamycin)
Fasudil HCl	R10-900	105628-07-7	C₁₄H₁₇N₃O₂S ∙ HCl	>98% (TLC); NMR (Conforms)	1. 1-(5-Isoquinolinesulfonyl) homopiperazine HCl 2. HA-1077
Flavopiridol HCl	C22-900	131740-09-5	C21H20ClNO5 · HCl	>98% (HPLC); NMR (Conforms)	2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3S, 4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one, hydrochloride; L 86-8275; Alvocidib; NSC-649890
Gefitinib	E10-900	184475-35-2	C₂₂H₂₄ClFN₄O₃	>98% (TLC); NMR (Conforms)	1. N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine; 2. ZD1839
Genistein	K11-900	446-72-0	C₁₅H₁₀O₅	98% (TLC); NMR (Conforms)	1. 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one 2. 4',5,7-Trihydroxyisoflavone
GF-109203X	P61-900	133052-90-1	C₂₅H₂₄N₄O₂	98% (TLC); NMR (Conforms)	1. 2-[1-(3-Dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide 2. Bisindolylmaleimide I
GSK-690693 HCl	A16-900	937174-76-0	C₂₁H₂₇N₇O₃ ^.HCl	99% (HPLC); NMR (Conforms)	(S)-4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(piperidin-3-ylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl)-2-methylbut-3-yn-2-ol. HCl
GW-441756	N28-909	504433-23-2	C₁₇H₁₃N₃O	98% (TLC: 5% CH₃OH: CH₂Cl₂; R_f=0.4) mixture of E and Z isomers	1,3-Dihydro-3-[(1-methyl-1H-indol-3-yl)methylene]-2H-pyrrolo[3,2-b]pyridin-2-one
GW-5074	R01-901B	220904-83-6	C₁₅H₈Br₂INO₂	98% (TLC); NMR (Conforms)	3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one
GW2580	C74-901	870483-87-7	C₂₀H₂₂N₄O₃	≥98% (TLC); NMR (Conforms)	5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine
H-89 2HCl	P51-900B	127243-85-0	C₂₀H₂₀BrN₃O₂S ∙ 2HCl	>98% (TLC); NMR (Conforms)	N-[2-[[3-(4-Bromophenyl)-2-propenyl] amino] ethyl]-5-isoquinolinesulfonamide dihydrochloride
HA-100 2HCl	K10-900F	84468-24-6	C₁₃H₁₅N₃O₂S • 2HCl	>98% (HPLC); NMR (conforms)	5-(1-Piperazinylsulfonyl)isoquinoline dihydrochloride
Hypericin	P61-900C	548-04-9	C₃₀H₁₆O₈	>98% (TLC); NMR (Conforms)	1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra] perylene-7,14-dione
IM-12	G09-901D	1129669-05-1	C22H20FN3O2	>98% (HPLC); NMR (conforms)	3-(4-Fluorophenylethylamino)-1-methyl-4-(2-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
Imatinib mesylate	A03-901B	220127-57-1	C₂₉H₃₁N₇O · CH₃SO₃H	98% (TLC); NMR (Conforms)	1. 4-[(4-Methyl-1-piperazinyl) methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide methanesulfonate 2. STI-571
Indirubin-3’-monoxime	C29-901	160807-49-8	C₁₆H₁₁N₃O₂	>98% (TLC); NMR (Conforms)	Indirubin-3’-oxime 3-[1,3-Dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one
IQ-1S	M35-901B	1421610-21-0	269.2	>98% (TLC); NMR (Conforms)	11H-Indeno[1,2-b]quinoxalin-11-one oxime, sodium salt
JNK Inhibitor IX	M34-901	312917-14-9	C₂₀H₁₆N₂OS	>98% (TLC); NMR (Conforms)	N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-1-naphthalenecarboxamide
JX-401	M39-901	349087-34-9	C₂₁H₂₅NO₂S	>98% (TLC); NMR (Conforms)	1-[2-Methoxy-4-(methylthio) benzoyl]-4-(phenylmethyl) piperidine
K252A	K10-900D	99533-80-9	C₂₇H₂₁N₃O₅	>98% (TLC); NMR (Conforms)	None
K252B	K10-900E	99570-78-2	C₂₆H₁₉N₃O₅	>98% (TLC); NMR (Conforms)	None
KT-5823	P78-900	126643-37-6	C₂₉H₂₅N₃O₅	>98% (TLC); NMR (Conforms)	None
KT5720	P51-900	108068-98-0	C₃₂H₃₁N₃O₅	>98% (TLC); NMR (Conforms)	None
KU-55933	A26-901	587871-26-9	C₂₁H₁₇NO₃S₂	>98% (TLC); NMR (conforms)	2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one
Lapatinib	E10-900D	231277-92-2	C₂₉H₂₆ClFN₄O₄S	98% (TLC); NMR (Conforms)	1. N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine 2. GW-572016
Lenvatinib	K01-901	417716-92-8	C₂₁H₁₉ClN₄O₄	>98% (TLC); NMR (conforms)	4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; E7080
Lestaurtinib	F12-901	111358-88-4	C₂₆H₂₁N₃O₄	>98% (TLC); NMR (Conforms)	1. CEP-701 2. KT-5555
LFM-A13	B10-901	62004-35-7	C₁₁H₈Br₂N₂O₂	98% (TLC: 2:8 CH₃OH:CH₂Cl₂; Rf=0.53); NMR (Conforms)	2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
LH-846	C67-901	639052-78-1	C₁₆H₁₃ClN₂OS	>98% (TLC); NMR (Conforms)	N-(5-Chloro-6-methyl-2-enzothiazolyl)benzeneacetamide
Locostatin	R01-901C	133812-16-5	C14H15NO3	>98% (TLC); NMR (conforms)	(4S)-3-[(E)-But-2-enoyl]-4-benzyl-2-oxazolidinone; UIC-1005
LY-294002	P27-900C	154447-36-6	C₁₉H₁₇NO₃	>98% (TLC); NMR (Conforms)	2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
LY-364947	T07-901	396129-53-6	C₁₇H₁₂N₄	>98% (TLC); NMR (Conforms)	4-(3-Pyridin-2-yl-1H-pyrazol-4-yl)quinolone; HTS-466284
LYS6K2	R15-900	NF	C₂₁H₁₉F₄N₇	>97% (HPLC); NMR (Conforms)	4-(4-(4-(4-fluoro-3-(trifluoromethyl) phenyl)-1-methyl-1H-imidazol-2-yl) piperidin-1-yl)-1H-pyrazolo [3,4-d] pyrimidine
MLS-573151	C08-909	NF	C₂₁H₁₉N₃O₂S	>98% (TLC); NMR (Conforms)	4-[3,5-diphenyl-4,5-dihydropyrazol-1-yl] benzenesulfonamide
Necrostatin-1	R07-901	4311-88-0	C₁₃H₁₃N₃OS	>98% (TLC: 1:9, CH₃OH:CH₂Cl2; Rf=0.6); NMR (Conforms)	1. 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxo-4-imidazolidinone 2. Methylthiohydantoin-DL-tryptophan
Nilotinib	A03-901	641571-10-0	C₂₈H₂₂F₃N₇O	>98% (TLC); NMR (Conforms)	1. 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl) phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino] benzamide 2. AMN-107
NPC-15437	P61-900B	141774-20-1	C₂₅H₅₀N₄O₂ ∙ 2HCl	98% (TLC); NMR (Conforms)	(S)-2,6-Diamino-N-[(1-(1-oxotridecyl)-2-piperidinyl) methyl] hexanamide dihydrochloride hydrate
NVP-BEZ235	F17-900	915019-65-7	C₃₀H₂₃N₅O	>98% (TLC); NMR (Conforms)	2-Methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c] quinolin-1-yl] phenyl} propanenitrile
Parthenolide	103-901B	20554-84-1	C15H20O3	>98% (TLC); NMR (conforms)	Sesquiterpene lactone found in feverfew (Tanacetum parthenium)
PD-325901	M02-901B	391210-10-9	C16H14F3IN2O4	≥98% (HPLC); NMR (Conforms)	N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide
PD-98059	M02-900	167869-21-8	C₁₆H₁₃NO₃	>98% (TLC); NMR (Conforms)	2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 2'-Amino-3'-methoxyflavone
Phorbol-12-myristate-13 acetate	P61-900D	16561-29-8	C36H56O8	>99% (HPLC); NMR (conforms)	12-O-Tetradecanoylphorbol-13-acetate; PMA; TPA
Piceatannol	I01-901	10083-24-6	C₁₄H₁₂O₄	>98% (TLC); NMR (Conforms)	3,3',4,5'-Tetrahydroxy-trans-stilbene
Picropodophyllotoxin	I02-901	477-47-4	C₂₂H₂₂O₈	>97% (TLC); NMR (Conforms)	(5R,5aS,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one
PKC-412	K10-900B	120685-11-2	C₃₅H₃₀N₄O₄	>98% (TLC); NMR (Conforms)	1. 4'-N-Benzoyl staurosporine 2. Midostaurin 3. CGP-41251
PP1	S19-900	172889-26-8	C₁₆H₁₉N₅	98% (TLC); NMR (Conforms)	4-Amino-1-tert-butyl-3-(4-methylphenyl) pyrazolo [3,4-d] pyrimidine
PP2	S19-900B	172889-27-9	C₁₅H₁₆ClN₅	>98% (TLC); NMR (Conforms)	3-(4-chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo [3,4-d] pyrimidin-4-amine
PX-866	P27-900	502632-66-8	C₂₉H₃₅NO₈	>98% (TLC); NMR (Conforms)	(1E,4S,4aR,5R,6aS,9aR)-5-(acetyloxy)-1-[(di-2-propen-1-ylamino) methylene]-4,4a,5,6,6a,8,9,9-a-octahydro-11-hydroxy-4-(methoxymethyl)-4a,6a-dimethyl-cyclopenta [5,6] naphtha [1,2-c] pyran-2,7,10(1H)-trione
R-59022	D21-900	93076-89-2	C27H26FN3OS	>98% (HPLC); NMR (conforms)	6-[2-[4-[(4-Fluorophenyl)phenylmethylene]-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one
Rapamycin	F17-901	53123-88-9	C₅₁H₇₉NO₁₃	>98% (TLC: 10% CH3OH in CH2Cl2; Rf=0.51); NMR (Conforms)	Sirolimus; Fermentation product
Regorafenib	K01-900	755037-03-7	C₂₁H₁₅ClF₄N₄O₃	>98% (HPLC,TLC); NMR (conforms)	4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide; BAY 73-4506
Reversine	A28-900	656820-32-5	C21H27N7O	>98% (HPLC, TLC); NMR (conforms)	2-(4-Morpholinoanilino)-6-cyclohexylaminopurine
Ro 31-6045	R21-901	113963-68-1	C₂₁H₁₅N₃O₂	>98% (HPLC, TLC); NMR (conforms)	1-Methyl-3,4-bis(indol-3-yl)maleimide; Bisindolylmaleimide V; BIM V
Roscovitine	C22-901	186692-46-6	C₁₉H₂₆N₆O	>99% (TLC); NMR (Conforms)	(R)-2-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl) amino) butan-1-ol
Ruxolitinib	J01-901	941678-49-5	C₁₇H₁₈N₆	>98% (HPLC,TLC); NMR (conforms)	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
SB-202190	M39-900B	152121-30-7	C₂₀H₁₄N₃OF	>98% (TLC: 10% CH₃OH in CH₂Cl₂, Rf=0.25); NMR (Conforms)	4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl] phenol
SB-203580	M39-900C	152121-47-6	C₂₁H₁₆N₃OSF	>98% (TLC); NMR (Conforms)	4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl) imidazole
SC-514	I03-901	354812-17-2	C₉H₈N₂OS₂	>98% (TLC; 5% CH3OH in CH2Cl2; Rf=0.27); NMR (Conforms)	5-(Thien-3-yl)-3-aminothiophene-2-carboxamide
Sorafenib	R01-900	284461-73-0	C₂₁H₁₆ClF₃N₄O₃	>99% (TLC); NMR (Conforms)	1. 4-(4-(3-(4-chloro-3 (trifluoromethyl) phenyl) ureido) phenoxy)-N-methylpicolinamide 2. BAY 43-9006
SP-600125	M33-900	129-56-6	C₁₄H₈N₂O	>98% (TLC); NMR (Conforms)	1. Anthra [1-9-cd] pyrazol-6(2H)-one 2. 1,9-Pyrazoloanthrone
SR-3576	M35-901	1164153-22-3	C₂₇H₂₇N₅O₅	>98% (TLC); NMR (Conforms)	3-(5-(3-m-Tolylureido)-1H-indazol-1-yl)-N-(3,4,5-trimethoxyphenyl)benzamide
Src I1	S19-901	179248-59-0	C₂₂H₁₉N₃O₃	≥98% (TLC; 5% CH₃OH in CH₂Cl₂; Rf=0.43); NMR (Conforms)	6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine
SRPIN340	S21-901	218156-96-8	C₁₈H₁₈F₃N₃O	>98% (TLC); NMR (Conforms)	N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide
Staurosporine	K10-900	62996-74-1	C₂₈H₂₆N₄O₃	>98% (TLC); NMR (Conforms)
STO-609	C17-900	52029-86-4	C₁₉H₁₀N₂O₃ ∙ CH₃COOH	98% (TLC); NMR (Conforms)	7-oxo-7H-benzimidazo[2,1-a]benz[de]isoquinoline-3-carboxylic acid acetate
SU-1498	F11-900E	NF	C₂₅H₃₀N₂O₂	>98% (TLC); NMR (Conforms)	(E)-N-(3-Phenylpropyl)-alpha-cyano-3',5'-diisopropyl-4'-hydroxycinnamamide
SU-4312	F11-900F	5812-07-7	C₁₇H₁₆N₂O	>98% (TLC); NMR (Conforms)	1. 3-(4-Dimethylaminobenzylidene)-1,3-dihydroindol-2-one 2. DMBI
Sunitinib malate	F11-900G	341031-54-7	C₂₂H₂₇FN₄O₂ ∙ C₄H₆O₅	>98% (TLC); NMR (Conforms)	1. N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide malate 2. SU-11248
TG003	C57-901	719277-26-6	C₁₃H₁₅NO₂S	>98% (HPLC); NMR (Conforms)	(Z)-1-(3-Ethyl-5-methoxy-2,3-dihydrobenzothiazol-2-ylidene)propan-2-one
U-0126	M02-901	109511-58-2	C₁₈H₁₆N₆S₂	>98% (TLC); NMR (Conforms)	1,4-Diamino-2,3-dicyano-1,4-bis [2-aminophenylthio] butadiene
Vandetanib	F11-900	443913-73-3	C₂₂H₂₄BrFN₄O₂	>98% (TLC); NMR (Conforms)	1. 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy] quinazoline 2. ZD6474
Vatalanib 2HCl	F11-900D	212141-51-0	C₂₀H₁₅CIN₄•2HCl	>98% (TLC); NMR (Conforms)	1. N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine dihydrochloride 2. CGP-79787 3. PTK-787 4. ZK222584
WHI-P131	J03-901	202475-60-3	C₁₆H₁₅N₃O₃ ∙ HCl	>98% (TLC); NMR (Conforms)	1. 4-[(4'-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, Hydrochloride 2. Janex-1
Wortmannin	P27-900B	19545-26-7	C₂₃H₂₄O₈	>98% (TLC); NMR (Conforms)	None
Y-27632 2HCl	R10-900B	129830-38-2	C₁₄H₂₁N₃O ∙ 2HCl	99% (HPLC); NMR (Conforms)	(R)-(+)-trans-4-(1-Aminoethyl)-N-(-4-pyridyl) cyclohexanecarboxamide dihydrochloride
ZM-306416	F11-900B	690206-97-4	C₁₆H₁₃ClFN₃O₂	>98% (TLC); NMR (Conforms)	4-[(4'-Chloro-2'-fluoro) phenylamino]-6,7-dimethoxyquinazoline
ZM-336372	R01-901	331771-20-1	C₂₃H₂₃N₃O₃	98% (TLC); NMR (Conforms)	3-(Dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]-benzamide
ZM-447439	A31-901	331771-20-1	C₂₉H₃₁N₅O₄	>98% (TLC); NMR (Conforms)	(N-[4-[[6-Methoxy-7-[3-(4-morpholinyl) propoxy]-4-quinazolinyl] amino] phenyl] benzamide

Compounds

Compounds

Compounds

Compounds

Subscribe to our mailing list!